Denali Therapeutics Statistics
NASDAQ: DNLIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
19.16-0.12 (-0.62%)
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Denali Therapeutics by the numbers
Denali Therapeutics has a market capitalization of $3.06 billion based on 159.85M shares outstanding. With trailing EPS of $-2.84, Denali Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 15.6% below its 50-day average and 9.1% below its 200-day average.
Average daily trading volume is 1.61M shares, or about $30.8 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
DNLI valuation vs. peer median
| Metric | DNLI | Peer median | Difference |
|---|---|---|---|
| Market cap | $3.06B | $2.28B | +34% |
| Avg. volume | 1.61M | 2.28M | -30% |
Peer median across 8 companies: TARS, BEAM, RXRX, ADMA, RLAY, BCRX, ALVO, VCEL.
Valuation
- Market cap
- $3.06B
- EPS (TTM)
- $-2.84
- Shares outstanding
- 159.85M
Price and trading
- Previous close
- 19.28
- Open
- 18.95
- Day range
- 18.89 – 19.43
- 52-week range
- 13.75 – 27.30
- 52-week change
- +28.62%
- Beta
- —
- Volume
- 1.31M
- Average volume
- 1.61M
Dividends and events
- Annual dividend
- None
- Next earnings date
- Nov 5, 2026
Additional statistics
- Market Cap
- 3.06B
- Forward Pe
- -7.92
- Eps
- -2.84
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 27.30
- Week52 Low
- 13.75
- Avg Volume
- 1.61M
- Shares Outstanding
- 159.85M
- Ma50
- 22.71
- Ma200
- 21.08
- Earnings Date
- Nov 5, 2026
- Pct From52w High
- -29.82%
- Pct From52w Low
- 39.35%